Open AccessExceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation
Author(s) -
Kmak Jamie A.,
Agarwal Nikita,
He Yuting,
Heilmann Andreas M.,
Miller Vincent A.,
Ross Jeffrey S.,
Pal Sumanta Kumar,
Ali Siraj M.,
Kilari Deepak
Publication year - 2020
Publication title -
case reports in oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.365
H-Index - 19
ISSN - 1662-6575
DOI - 10.1159/000506625
Subject(s) - case report
Prostate cancer is among the most common types of cancer in men. Early detection and proper medical intervention is crucial to ensuring successful treatment. Here we describe a patient clinically presenting with castrate-resistant prostate carcinoma. Comprehensive genomic profiling identified a PTEN inactivating mutation in the patient’s tumor. After being heavily pretreated, the patient showed stable disease on everolimus, a PI3K-Akt-mTOR pathway inhibitor.